Most mRNA design sucks.
Disappointed by expression levels? Frustrated by immunogenicity? It’s not bad luck—it’s sequence design.
Those “codon optimized” sequences from established vendors? They’re built for manufacturing convenience, not your therapeutic success.
"RNA manufacturing is still an art, not just a science" - @john_evans3
Read more about Terrain Bio and the challenge of designing and building high quality RNA for developing new medicines in @statnews by @ADeAngelis_bio
Low-quality mRNA doesn’t give you “good results with bad quality we can figure out later.” It gives you something else entirely: an experiment that isn’t yours. This adds to timelines, burns cash, and doesn't advance your science.
Learn more about how we make high-quality mRNA:
That’s why Terrain Bio is built on a philosophy more akin to West Coast tech than traditional pharma. We aren’t focused on nurturing our own proprietary pipeline; instead, we’re crafting a product for scientists: better RNA, delivered faster.
Your mRNA sequence is silently bleeding your runway dry. Startups are burning $Ms fixing problems they could have avoided for a fraction of the cost. Don't be next. 👇
When we analyzed sequences from leading vendors, we found integrity as low as ~50%. After Terrain’s mRNA design & build services, we delivered the correct sequence at >90%.
The difference? The fate of your mRNA therapy.
Our mission is to provide scalable, high-quality infrastructure for designing and delivering RNA that frees researchers developing RNA medicines from reinventing the wheel 🧵
In science, as in software, you wouldn’t expect innovators to start from scratch every time. You wouldn’t homebrew your molecular biology kits or train AI models from raw code. Just like in our science, we should be standing on the shoulders of giants.
It’s getting easier and easier to simulate biology, but the work of actually building molecules, developing and manufacturing real medicines remains incredibly challenging.